S
Stephan Ortiz
Researcher at Alexion Pharmaceuticals
Publications - 26
Citations - 535
Stephan Ortiz is an academic researcher from Alexion Pharmaceuticals. The author has contributed to research in topics: Eculizumab & Paroxysmal nocturnal hemoglobinuria. The author has an hindex of 7, co-authored 18 publications receiving 249 citations.
Papers
More filters
Journal ArticleDOI
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Austin G. Kulasekararaj,Anita J. Hill,Scott T. Rottinghaus,Saskia Langemeijer,Richard A. Wells,F. Ataulfo Gonzalez-Fernandez,Anna Gaya,Jong Wook Lee,Emilio Ojeda Gutierrez,Caroline I. Piatek,Jeff Szer,Antonio M. Risitano,Shinji Nakao,Eric Bachman,Lori Shafner,Andrew I. Damokosh,Stephan Ortiz,Alexander Röth,Régis Peffault de Latour +18 more
TL;DR: Patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered every 2 weeks to ravulizumabs administered every 8 weeks, and no meningococcal infections or discontinuations due to adverse events occurred.
Journal ArticleDOI
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Eric Rondeau,Marie Scully,Gema Ariceta,Thomas D. Barbour,Spero R. Cataland,Nils Heyne,Yoshitaka Miyakawa,Stephan Ortiz,Eugene Swenson,Marc Vallee,Sung-Soo Yoon,David J. Kavanagh,Hermann Haller,Sunil Babu,Nilufer Broeders,Nicole Lietar,Fiona G. Brown,Philip Campbell,Paramit Chowdhury,Theo Kasimatis,Lino Cirami,Leonardo Caroti,Guilia Antognoli,Yahsou Delmas,Vladimir A. Dobronravov,Anja Gaeckler,Cyril Garrouste,Gregory Greenwood,Siân V. Griffin,Chiu-Ching Huang,I-Ru Chen,Susan Huang,Jin Seok Kim,Gaetano La Manna,Giorgia Comai,Maria Cappuccilli,Moglie Le Quintrec,Guillaume Jeantet,Iino Fumie,Yosu Luque,Jan Menne,Johan Morelle,Eric Goffin,Anja Muhlfeld,Shashi K. Nagaraj,Gowthami M. Arepally,Doyeun Oh,Masayoshi Okumi,Manuel Praga Terente,Elena Gutierréz,Paola Rodriguez,François Provôt,Ulf Schönermarck,Michael Fischereder,Natalia Ramos Terrada,Barbara Seitz-Polski,Guillaume Favre,Sonia Boyer-Suavet,Maria Vinogradova,Tatiana Kirsanova,Edwin K.S. Wong +60 more
TL;DR: Treatment with ravulizumab once every eight weeks resulted in rapidly improved hematologic and renal endpoints with no unexpected adverse events in adults with atypical hemolytic uremic syndrome.
Journal ArticleDOI
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky,Régis Peffault de Latour,Scott T. Rottinghaus,Alexander Röth,Antonio M. Risitano,Ilene C. Weitz,Peter Hillmen,Jaroslaw P. Maciejewski,Jeff Szer,Jong Wook Lee,Austin G. Kulasekararaj,Lori Volles,Andrew I. Damokosh,Stephan Ortiz,Lori Shafner,Peng Liu,Anita Hill,Hubert Schrezenmeier +17 more
TL;DR: The results suggest that the immediate, complete, and sustained C5 inhibition achieved through weight-based dosing of ravulizumab reduces the risk of BTH by eliminating BTH associated with suboptimal C4 inhibition in patients with PNH.
Journal ArticleDOI
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Kazuki Tanaka,Brigitte Adams,Alvaro Madrid Aris,Naoya Fujita,Masayo Ogawa,Stephan Ortiz,Marc Vallee,Larry A. Greenbaum +7 more
TL;DR: Overall, treatment with ravulizumab in pediatric patients with aHUS who were previously treated with eculizumAB resulted in stable kidney and hematologic parameters, with no unexpected safety concerns when administered every 4–8 weeks.
Journal ArticleDOI
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
Régis Peffault de Latour,Robert A. Brodsky,Stephan Ortiz,Antonio M. Risitano,Jun H. Jang,Peter Hillmen,A. D. Kulagin,Austin G. Kulasekararaj,Scott T. Rottinghaus,Rasha Aguzzi,Xiang Gao,Richard A. Wells,Jeff Szer +12 more
TL;DR: RavulIZumab q8w was more consistent in providing immediate, complete, sustained C5 inhibition than eculizumab every‐2‐weeks in patients with PNH.